Safety and Plasma Concentrations of a Cyclin-dependent Kinase 9 (CDK9) Inhibitor, FIT039, Administered by a Single Adhesive Skin Patch Applied on Normal Skin and Cutaneous Warts
ConclusionThe FIT039 patch showed no topical or systemic adverse reactions when applied on normal skin or cutaneous warts. The safety and good adherence of the FIT039 patch are encouraging and support further studies to evaluate the efficacy of FIT039 in patients with cutaneous warts.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
More News: Clinical Trials | Cryotherapy | Drugs & Pharmacology | Human Papillomavirus (HPV) | Skin | Study | Warts